Pramipexole-induced increased probabilistic discounting: Comparison between a rodent model of parkinson's disease and controls

Neuropsychopharmacology

Volumn 37, Issue 6, 2012, Pages 1397-1408

  Rokosik, Sandra L ^a,b   Napier, T Celeste ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

6 OHDA; gambling; pramipexole; probability discounting; rat; reward

Indexed keywords

6 HYDROXYDOPA; PRAMIPEXOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY POSTURE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DRUG REEXPOSURE; DRUG TOLERANCE; FACE VALIDITY; HEMISPHERE; MALE; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROBABILITY; PROPENSITY SCORE; RAT; SELF STIMULATION;

ADRENERGIC AGENTS; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; BIOPHYSICS; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; ELECTRODES, IMPLANTED; IMPULSE CONTROL DISORDERS; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; PROBABILITY LEARNING; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; RISK-TAKING; SELF ADMINISTRATION;

EID: 84859740086     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.325     Document Type: Article

References (49)

1. Abler B, Hahlbrock R, Unrath A, Gron G, Kassubek J (2009). At-risk for pathological gambling: imaging neural reward processing under chronic dopamine agonists. Brain 132: 2396-2402.
2. Bodi N, Keri S, Nagy H, Moustafa A, Myers CE, Daw N et al (2009). Reward-learning and the novelty-seeking personality: a betweenand within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain 132: 2385-2395.
3. Bonuccelli U, Del DP, Rascol O (2009). Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Parkinsonism Relat Disord 15(Suppl 4): S44-S53.
4. Buckholtz JW, Treadway MT, Cowan RL, Woodward ND, Li R, Ansari MS et al (2010). Dopaminergic network differences in human impulsivity. Science 329: 532.
5. Caine SB, Koob GF, Parsons LH, Everitt BJ, Schwartz JC, Sokoloff P (1997). D3 receptor test in vitro predicts decreased cocaine selfadministration in rats. Neuroreport 8: 2373-2377. (Pubitemid 27319704)
6. Chang JW, Wachtel SR, Young D, Kang UJ (1999). Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88: 617-628. (Pubitemid 28480020)
7. Chernoloz O, El MM, Blier P (2009). Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain. Neuropsychopharmacology 34: 651-661.
8. Collins GT, Calinski DM, Newman AH, Grundt P, Woods JH (2008). Food restriction alters N0-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride (pramipexole)-induced yawning, hypothermia, and locomotor activity in rats: evidence for sensitization of dopamine D2 receptor-mediated effects. J Pharmacol Exp Ther 325: 691-697. (Pubitemid 351574782)
9. Collins GT, Newman AH, Grundt P, Rice KC, Husbands SM, Chauvignac C et al (2007). Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) 193: 159-170. (Pubitemid 47025018)
10. Collins GT, Truccone A, Haji-Abdi F, Newman AH, Grundt P, Rice KC et al (2009). Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice. J Pharmacol Exp Ther 329: 210-217.
11. Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J et al (2005). Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther 314: 310-319. (Pubitemid 41058268)
12. Cools R, Altamirano L, D'Esposito M (2006). Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia 44: 1663-1673. (Pubitemid 43928015)
13. Deumens R, Blokland A, Prickaerts J (2002). Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175: 303-317. (Pubitemid 34634286)
14. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE (2005). Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62: 1377-1381. (Pubitemid 41352054)
15. Driver-Dunckley ED, Noble BN, Hentz JG, Evidente VG, Caviness JN, Parish J et al (2007). Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 30: 249-255. (Pubitemid 47511504)
16. Evans AH, Strafella AP, Weintraub D, Stacy M (2009). Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 24: 1561-1570.
17. Ghods-Sharifi S, St Onge JR, Floresco SB (2009). Fundamental contribution by the basolateral amygdala to different forms of decision making. J Neurosci 29: 5251-5259.
18. Hamidovic A, Kang UJ, de WH (2008). Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. J Clin Psychopharmacol 28: 45-51.
19. Heidbreder CA, Gardner EL, Xi ZX, Thanos PK, Mugnaini M, Hagan JJ et al (2005). The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev 49: 77-105. (Pubitemid 40800164)
20. Heidbreder CA, Newman AH (2010). Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann NY Acad Sci 1187: 4-34.
21. Holman AJ (2009). Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud 25: 425-431.
22. Holt DD, Green L, Myerson J (2003). Is discounting impulsive? Evidence from temporal and probability discounting in gambling and non-gambling college students. Behav Processes 64: 355-367. (Pubitemid 37324379)
23. Johnson PS, Madden GJ, Brewer AT, Pinkston JW, Fowler SC (2011). Effects of acute pramipexole on preference for gamblinglike schedules of reinforcement in rats. Psychopharmacology (Berl) 231: 11-18.
24. Kish SJ, Shannak K, Hornykiewicz O (1988). Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318: 876-880. (Pubitemid 18090271)
25. Macphee GJ, Copeland C, Stewart D, Grosset K, Grosset DG (2009). Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. Mov Disord 24: 2430-2431.
26. Madden GJ, Petry NM, Johnson PS (2009). Pathological gamblers discount probabilistic rewards less steeply than matched controls. Exp Clin Psychopharmacol 17: 283-290.
27. Maj J, Rogoi Z, Margas W, Kata M, Dziedzicka-Wasylewska M (2000). The effect of repeated treatment with pramipexole on the central dopamine D3 system. J Neural Transm 107: 1369-1379. (Pubitemid 32049933)
28. Mamikonyan E, Siderowf AD, Duda JE, Potenza MN, Horn S, Stern MB et al (2008). Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 23: 75-80. (Pubitemid 351281221)
29. Olsson M, Nikkhah G, Bentlage C, Bjorklund A (1995). Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15: 3863-3875.
30. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Academic Press: New York.
31. Petry NM (2011). Discounting of probabilistic rewards is associated with gambling abstinence in treatment-seeking pathological gamblers. J Abnorm Psychol; e-pub ahead of print 15 August 2011.
32. Pizzagalli DA, Evins AE, Schetter EC, Frank MJ, Pajtas PE, Santesso DL et al (2008). Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. Psychopharmacology (Berl) 196: 221-232.
33. Pourcher E, Remillard S, Cohen H (2010). Compulsive habits in restless legs syndrome patients under dopaminergic treatment. J Neurol Sci 290: 52-56.
34. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D et al (1995). Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67: 631-647.
35. Quickfall J, Suchowersky O (2007). Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord 13: 535-536. (Pubitemid 350110554)
36. Riba J, Kramer UM, Heldmann M, Richter S, Munte TF (2008). Dopamine agonist increases risk taking but blunts rewardrelated brain activity. PLoS ONE 3: e2479.
37. Riddle JL, Rokosik SL, Napier TC (2010). Pramipexole induces a conditioned place preference in parkinsonian-like and control rats. Program No 813 21, 2010. Neuroscience Meeting Planner, San Diego, CA: Society for Neuroscience, 2010 Online.
38. Rokosik SL, Napier TC (2011). Intracranial self-stimulation as a positive reinforcer to study impulsivity in a probability discounting paradigm. J Neurosci Methods 198: 260-269.
39. Santesso DL, Evins AE, Frank MJ, Schetter EC, Bogdan R, Pizzagalli DA (2009). Single dose of a dopamine agonist impairs reinforcement learning in humans: evidence from event-related potentials and computational modeling of striatal-cortical function. Hum Brain Mapp 30: 1963-1976.
40. Seedat S, Kesler S, Niehaus DJ, Stein DJ (2000). Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 11: 185-186. (Pubitemid 30612771)
41. Self DW (1998). Neural substrates of drug craving and relapse in drug addiction. Ann Med 30: 379-389. (Pubitemid 28416528)
42. St Onge JR, Chiu YC, Floresco SB (2010). Differential effects of dopaminergic manipulations on risky choice. Psychopharmacology (Berl) 211: 209-221.
43. St Onge JR, Floresco SB (2009). Dopaminergic modulation of riskbased decision making. Neuropsychopharmacology 34: 681-697.
44. Strejilevich SA, Martino DJ, Igoa A, Manes F (2011). Pathological gambling in a bipolar patient treated with pramipexole. J Neuropsychiatry Clin Neurosci 23: E2-E3.
45. Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH (2007). Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 68: 301-303. (Pubitemid 46148346)
46. Van Eimeren T, Ballanger B, Pellecchia G, Miyasaki JM, Lang AE, Strafella AP (2009). Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology 34: 2758-2766.
47. Van Gaalen MM, Unger L, Jongen-Relo AL, Schoemaker H, Gross G (2009). Amphetamine decreases behavioral inhibition by stimulation of dopamine D2, but not D3, receptors. Behav Pharmacol 20: 484-491.
48. Voon V, Fox SH (2007). Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 64: 1089-1096. (Pubitemid 47258066)
49. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V et al (2010). Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67: 589-595.